Open AccessCancer immunotherapy in routine cost‐effective cancer care?
Author(s) -
Feldmann Sir Marc
Publication year - 2018
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.15252/emmm.201809660
Subject(s) - cancer , immunotherapy , cancer immunotherapy , medicine , cancer research , oncology , intensive care medicine
Therapy‐triggered autoimmunity and inflammation in many cancer patients, as well as treatment costs, hamper the success of cancer immunotherapy. The study by Pfeiffer et al in this issue of EMBO Molecular Medicine constitutes a clear step towards a more simple, scalable and affordable approach in generating in situ T cells reprogrammed with chimeric antigen receptors ( CAR s) (Pfeiffer et al , [Pfeiffer A, 2018]).